Subject(s)
Bridged Bicyclo Compounds, Heterocyclic , Leukemia, Myeloid, Acute , Myelodysplastic Syndromes , Propensity Score , Sulfonamides , Humans , Bridged Bicyclo Compounds, Heterocyclic/therapeutic use , Bridged Bicyclo Compounds, Heterocyclic/administration & dosage , Leukemia, Myeloid, Acute/drug therapy , Myelodysplastic Syndromes/drug therapy , Myelodysplastic Syndromes/diagnosis , Sulfonamides/therapeutic use , Sulfonamides/administration & dosage , Male , Aged , Female , Middle Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Adult , Aged, 80 and overABSTRACT
Cardiotoxicity is one of the primary limitations in the clinical use of the anticancer drug doxorubicin (DOX). However, the role of microRNAs (miRNAs) in DOX-induced cardiomyocyte death has not yet been covered. To investigate this, we observed a significant increase in miR-98 expression in neonatal rat ventricular myocytes after DOX treatment, and MTT, LIVE/Dead and Viability/Cytotoxicity staining showed that miR-98 mimic inhibited DOX-induced cell death. This was also confirmed by Flow cytometry and Annexin V-FITC/PI staining. Interestingly, the protein expression of caspase-8 was upregulated by miR-98 mimics during this process, whereas Fas and RIP3 were downregulated. In addition, the effect of miR-98 against the expression of Fas and RIP3 were restored by the specific caspase-8 inhibitor Z-IETD-FMK. Thus, we demonstrate that miR-98 protects cardiomyocytes from DOX-induced injury by regulating the caspase-8-dependent Fas/RIP3 pathway. Our findings enhance understanding of the therapeutic role of miRNAs in the treatment of DOX-induced cardiotoxicity.
Subject(s)
Antibiotics, Antineoplastic , Cardiotoxicity/genetics , Caspase 8/metabolism , Doxorubicin , MicroRNAs , Myocytes, Cardiac/metabolism , Animals , Cardiotoxicity/metabolism , Cell Survival , Cells, Cultured , Membrane Potential, Mitochondrial , Myocytes, Cardiac/physiology , Rats, Sprague-Dawley , Receptor-Interacting Protein Serine-Threonine Kinases/metabolism , Signal Transduction , fas Receptor/metabolismABSTRACT
The geometrical structures, electronic structures, optoelectronic properties and phosphorescence efficiencies of four blue-emitting phosphors [Ir(fpmi)2(pyim)] (1), [Ir(pyim)2(fpmi)] (2), [Ir(fpmi)2(fptz)] (3), [Ir(tfmppz)2(pyim)] (4), [fpmi = 1-(4-fluorophenyl)-3-methylimdazolin-2-ylidene-C,C2'; pyim = 2-(1H-imidazol-2-yl)pyridinato; fptz = 5-(trifluoromethyl-2H-1,2,4-triazol-3-yl)pyridine; tfmppz = 1-(4-trifluoromethylphenyl)pyrazolyl] were investigated by DFT and TDDFT methods. We first optimized geometrical structures in the ground and lowest triplet states, and computed the absorption and emission spectra of 1 and 5[Ir(fpmi)2(pypz)] [pypz = 2-(1H-pyrazol-5-yl)pyridinato], which have been synthesized and characterized in a laboratory, using three functionals, B3LYP, CAM-B3LYP, and M062X. The calculation results were compared with relevant experimental data to assess the performance of the functionals. The suitable methods and functionals were then applied to study properties of the three other complexes. The HOMOs of 1-3 are composed of d(Ir) and π(cyclometalated ligands), however, the HOMO of 4 resides on the pyim ligand, while the LUMOs of all four complexes are dominantly localized on the chelating ligands. The calculated absorption results show that the corresponding absorption peaks for the four mainly studied complexes are almost at the same positions, however, the absorption intensities of the bands differ largely from each other. The lowest energy emissions of the four complexes are localized at 507, 512, 468, and 513 nm, respectively. In order to estimate their efficiencies, we carried out simplified radiative rate constant calculations. It turns out that complex 3, which possesses the shortest emission wavelength and the largest radiative rate constant (k r) value, can be considered as a highly efficient blue-emitting iridium(iii) complex.